title: Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study.
abstract: BACKGROUND
  Health-related quality of life (HRQOL) measurements provide valuable information about the psychological and social impact of treatment on patients with cystic fibrosis (CF). This study evaluated the HRQOL of Brazilian patients with CF and assessed the changes in HRQOL domains over 1 year after dornase alfa (Pulmozyme) introduction.
  
  
  METHODS
  One hundred fifty-six stable patients with CF and 89 caregivers answered the Portuguese-validated version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at baseline (T(0)), and at 3 (T(1)), 6 (T(2)), 9 (T(3)), and 12 (T(4)) months of follow-up. Eighteen patients were excluded because they did not fulfill the inclusion criteria. The patients were analyzed in two groups: those aged 6-11 years and those aged 14 years and older. ANOVA for observed repeated results and the last observation carried forward (LOCF) method for missing data were used for the statistical analysis.
  
  
  RESULTS
  After 1 year of follow-up, there was significant improvement in respiratory symptoms (T(4) - T(0) = 8.1; 95% confidence interval (95% CI) = [2.1;14.0]; effect size (ES) = 0.35; P < 0.001), Emotional Functioning (T(4) - T(0) = 5.6; 95% CI = [1.1;10.1]; ES = 0.31; P < 0.05), Social Functioning (T(4) - T(0) = 6.0; 95% CI = [1.3;11.7]; ES = 0.31; P < 0.05), Body Image (T(4) - T(0) = 11.9; 95% CI = [4.1;19.7]; ES = 0.42; P < 0.05), and Treatment Burden (T(4) - T(0) = 5.3; 95% CI = [0.3;10.3]; ES = 0.24; P < 0.05) domains in the younger group. A significant improvement in Role Functioning (T(4) - T(0) = 6.1; 95% CI = [1.1;11.1]; ES = 0.40; P < 0.05), Body Image (T(4) - T(0) = 12.6; 95% CI = [3.5;21.7]; ES = 0.46; P < 0.05), and Weight (T(4) - T(0) = 11.7; 95% CI = [1.8;21.6]; ES = 0.40; P < 0.05) was obtained in the older group. The caregivers' CFQ-R showed improvements in the Digestive Symptoms (T(4) - T(0) = 5.5; 95% CI = [1.5;9.4]; ES = 0.30; P < 0.05), Respiratory Symptoms (T(4) - T(0) = 7.6; 95% CI = [3.9;11.4]; ES = 0.48; P < 0.05), and Weight (T(4) - T(0) = 10.1; 95% CI = [1.6;18.6]; ES = 0.26; P < 0.05) domains.
  
  
  CONCLUSIONS
  The introduction of dornase alfa improved the HRQL of the patients with CF during the first year of treatment.
authors.affiliation: São Paulo, UNIFESP/EPM. rozov@uol.com.br
authors.forename: Tatiana
authors.initials: T
authors.lastname: Rozov
authors.forename: Viviane Ziebell
authors.initials: VZ
authors.lastname: de Oliveira
authors.forename: Maria Angélica
authors.initials: MA
authors.lastname: Santana
authors.forename: Fabíola Villac
authors.initials: FV
authors.lastname: Adde
authors.forename: Rita Heloisa
authors.initials: RH
authors.lastname: Mendes
authors.forename: Ilma Aparecida
authors.initials: IA
authors.lastname: Paschoal
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Caldeira Reis
authors.forename: Laurinda Yoko Shinzato
authors.initials: LY
authors.lastname: Higa
authors.forename: Antonio Carlos de Castro
authors.initials: AC
authors.lastname: Toledo
authors.forename: Márcia
authors.initials: M
authors.lastname: Pahl
mesh_terms: D000293:Adolescent; D001938:Brazil; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003850:Deoxyribonuclease I / Q000627:therapeutic use*; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D005100:Expectorants; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I